FGF23 and X-linked hypophosphatemia: However, in April 2018, the United States FDA approved burosumab (Crysvita®, Ultragenyx, Novato, CA, USA), which is a human monoclonal IgG1 antibody against FGF23, for treatment of adults and children with XLH.